Network-principled deep generative models for designing drug
  combinations as graph sets by Karimi, Mostafa et al.
ar
X
iv
:2
00
4.
07
78
2v
2 
 [q
-b
io.
M
N]
  2
2 A
pr
 20
20
Bioinformatics
doi.10.1093/bioinformatics/xxxxxx
Network-principled deep generative models for
designing drug combinations as graph sets
Mostafa Karimi 1,2,=, Arman Hasanzadeh 1,= and Yang shen 1,2,*
1Department of Electrical and Computer Engineering and 2TEES–AgriLife Center for Bioinformatics and Genomic Systems
Engineering, Texas A&M University, College Station, 77843, USA.
=Co-first authors.
∗To whom correspondence should be addressed.
Associate Editor: XXXXXXX
Received on XXXXX; revised on XXXXX; accepted on XXXXX
Abstract
Motivation: Combination therapy has shown to improve therapeutic efficacy while reducing side effects.
Importantly, it has become an indispensable strategy to overcome resistance in antibiotics, anti-microbials,
and anti-cancer drugs. Facing enormous chemical space and unclear design principles for small-molecule
combinations, computational drug-combination design has not seen generative models to meet its
potential to accelerate resistance-overcoming drug combination discovery.
Results: We have developed the first deep generative model for drug combination design, by jointly
embedding graph-structured domain knowledge and iteratively training a reinforcement learning-based
chemical graph-set designer. First, we have developed Hierarchical Variational Graph Auto-Encoders
(HVGAE) trained end-to-end to jointly embed gene-gene, gene-disease, and disease-disease networks.
Novel attentional pooling is introduced here for learning disease-representations from associated
genes’ representations. Second, targeting diseases in learned representations, we have recast the
drug-combination design problem as graph-set generation and developed a deep learning-based
model with novel rewards. Specifically, besides chemical validity rewards, we have introduced novel
generative adversarial award, being generalized sliced Wasserstein, for chemically diverse molecules
with distributions similar to known drugs. We have also designed a network principle-based reward
for drug combinations. Numerical results indicate that, compared to state-of-the-art graph embedding
methods, HVGAE learns more informative and generalizable disease representations. Results also show
that the deep generative models generate drug combinations following the principle across diseases.
Case studies on four diseases show that network-principled drug combinations tend to have low toxicity.
The generated drug combinations collectively cover the disease module similar to FDA-approved drug
combinations and could potentially suggest novel systems-pharmacology strategies. Our method allows
for examining and following network-based principle or hypothesis to efficiently generate disease-specific
drug combinations in a vast chemical combinatorial space.
Availability: https://github.com/Shen-Lab/Drug-Combo-Generator
Contact: yshen@tamu.edu
Supplementary information: Supplementary data are available at
https://github.com/Shen-Lab/Drug-Combo-Generator/blob/master/SI_drugcomb_RL.pdf
1 Introduction
Drug resistance is a fundamental barrier to developing robust antimicrobial
and anticancer therapies (Taubes, 2008; Housman et al., 2014). Its
first sign was observed in 1940s soon after the discovery of
penicillin (Abraham and Chain, 1940), the first modern antibiotic.
Since then, drug resistance has surfaced and progressed in infectious
diseases such as HIV (Clavel and Hance, 2004), tuberculosis
(TB) (Dooley et al., 1992) and hepatitis (Ghany and Liang, 2007) as
well as cancers (Holohan et al., 2013). Mechanistically, it can emerge
through drug efflux (Chang and Roth, 2001), activation of alternative
pathways (Lovly and Shaw, 2014) and protein mutations (Toy et al., 2013;
Balbas et al., 2013) while decreasing the efficacy of drugs.
Combination therapy is a resistance-overcoming strategy that
has found success in combating HIV (Shafer and Vuitton, 1999),
TB (Ramón-García et al., 2011), cancers (Sharma and Allison, 2015;
Bozic et al., 2013) and so on. Considering that most diseases and
their resistances are multifactorial (Kaplan and Junien, 2000; Keith et al.,
2005), multiple drugs targeting multiple components simultaneously
could confer less resistance than individual drugs targeting components
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separately. Examples include targeting both MEK and BRAF in patients
with BRAF V600-mutant melanoma rather than targeting MEK or
BRAF alone (Madani Tonekaboni et al., 2018; Flaherty et al., 2012).
The effect of drug combination is usually categorized as synergistic,
additive, or antagonistic depending on whether it is greater than,
equal to or less than the sum of individual drug effects (Chou,
2006). Synergistic combinations are effective at delaying the beginning
of the resistance, however antagonistic combinations are effective at
suppressing expansion of resistance (Saputra et al., 2018; Singh and Yeh,
2017), representing offensive and defensive strategies to overcome drug
resistance. In particular, offensive strategies cause huge early causalities
but defensive ones anticipate and develop protection against future threats.
(Saputra et al., 2018).
Discovering a drug combination to overcome resistance is however
extremely challenging, even more so than discovering a drug which
is already a costly (∼billions of USD) (DiMasi et al., 2016) and
lengthy (∼12 years) (Van Norman, 2016) process with low success rates
(3.4% phase-1 oncology compounds make it to approval and market)
(Wong et al., 2019). An apparent challenge, a combinatorial one, is in
the scale of chemical space, which is estimated to be 1060 for single
compounds (Bohacek et al., 1996) and can “explode” to 1060K for K-
compound combinations. Even if the space is restricted to around 103
FDA-approved human drugs, there are 105–106 pairwise combinations.
Another challenge, a conceptual one, is in the complexity of systems
biology. On top of on-target efficacy and off-target side effects or even
toxicity that need to be considered for individual drugs, network-based
design principles are much needed for drug combinations that effectively
target multiple proteins in a disease module and have low toxicity
or even resistance profiles (Martínez-Jiménez and Marti-Renom, 2016;
Billur Engin et al., 2014).
Current computational models in drug discovery, especially those
for predicting pharmacokinetic and pharmacodynamic properties of
individual drugs/compounds, can be categorized into discriminative
and generative models. Discriminative models predict the distribution
of a property for a given molecule whereas generative models would
learn the joint distribution on the property and molecules. For
instance, discriminative models have been developed for predicting single
compounds’ toxicities, based on support vector machines (Darnag et al.,
2010), random forest (Svetnik et al., 2003) and deep learning (Mayr et al.,
2016). Whereas discriminative models are useful for evaluating given
compounds or even searching compound libraries, generative models
can effectively design compounds of desired properties in chemical
space. Recent advance in inverse molecular design has seen deep
generative models such as SMILES representation-based reinforcement
learning (Popova et al., 2018) or recurrent neural networks (RNNs)
as well as graph representation-based generative adversarial network
(GANs), reinforcement learning (You et al., 2018), and generative
tensorial reinforcement learning (GENTRL) (Zhavoronkov et al., 2019).
Unlike single drug design, current computational efforts for drug
combinations are exclusively focused on discriminative models and lack
generative models. The main focus for drug combination is to use
discriminate models to identify synergistic or antagonistic drugs for a
given specific disease. Examples include the Chou-Talalay method (Chou,
2010), integer linear programming (Pang et al., 2014), and deep learning
(Preuer et al., 2017) and . However, it is daunting if not infeasible to
enumerate all cases in the enormous chemical combinatorial space and
evaluate their combination effects using a discriminative model. Not to
mention that such methods often lack explainability.
Directly addressing aforementioned combinatorial and conceptual
challenges and filling the void of generative models for drug combinations,
in this study, we develop network-based representation learning for
diseases and deep generative models for accelerated and principled drug
combination design (the general case ofK drugs). Recently, by analyzing
the network-based relationships between disease proteins and drug targets
in the human protein–protein interactome, Cheng et al. proposed an
elegant principle for FDA-approved drug combinations that targets of
two drugs both hit the disease module but cover different neighborhoods.
Our methods allow for examining and following the proposed network-
based principle (Cheng et al., 2019) to efficiently generate disease-specific
drug combinations in a vast chemical combinatorial space. They will
also help meet a critical need of computational tools in a battle against
quickly evolving bacterial, viral and tumor populations with accumulating
resistance.
To tackle the problem, we have developed a network principle-based
deep generative model for faster, broader and deeper exploration of drug
combination space by following the principle underling FDA approved
drug combinations. First, we have developed Hierarchical Variational
Graph Auto-Encoders (HVGAE) for jointly embedding disease-disease
network and gene-gene network. Through end-to-end training, we embed
genes in a way that they can represent the human interactome. Then,
we utilize their embeddings with novel attentional pooling to create
features for each disease so that we can embed diseases more accurately.
Second, we have also developed a reinforcement-learning based graph-
set generator for drug combination design by utilizing both gene/disease
embedding and network principles. Besides those for chemical validity
and properties, our rewards also include 1) a novel adversarial reward,
generalized sliced Wasserstein distance, that fosters generated molecules
to be diverse yet similar in distribution to known compounds (ZINC
database and FDA-approved drugs) and 2) a network principle-based
reward for drug combinations that are feasible for online calculations.
The overall schematics are shown in Fig. 1 and details in Sec. 3.
2 Data
2.1 Human interactome and its features
We used the human interactome data (a gene-gene network) from
(Menche et al., 2015) that feature 13,460 proteins interconnected by
141,296 interactions.
We introduced edge features for the human interactome based on the
biological nature of edges (interactions). The interactomewas compiled by
combining experimental support from various sources/databases including
1) regulatory interactions fromTRANSFAC(Matys et al., 2003); 2) binary
interactions from high-throughput (including (Rolland et al., 2014)) and
literature-curated datasets (including IntAct (Aranda et al., 2010) and
MINT (Ceol et al., 2010)) as well as literature-curated interactions from
low-throughput experiments (IntAct, MINT,BioGRID (Stark et al., 2010),
and HPRD (Keshava Prasad et al., 2009)); 3) metabolic enzyme-coupled
interactions from (Lee et al., 2008); 4) protein complexes from CORUM
(Ruepp et al., 2010); 5) kinase-substrate pairs from PhosphositePlus
(Hornbeck et al., 2012); and 6) signaling interactions. In summary, an edge
couldcorrespond tooneormultiple physical interaction types. Soweuseda
6-hot encoding for edge features, based on whether an edge corresponds to
regulatory, binary, metabolic, complex, kinase and signaling interactions.
Wealso introduced features for nodes (genes) in the human interactome
based on1)KEGGpathways (Kanehisa et al., 2002) (336 features) queried
through Biopython (Cock et al., 2009); 2) Gene Ontology (GO) terms
(Ashburner et al., 2000) including biological process (30,769 features),
molecular function (12,183 features), and cellular component (4,451
features), mapped using the NCBI Gene2Go dataset; 3) disease-gene
associations from the database OMIM (Mendelian Inheritance in Man)
(Hamosh et al., 2005) and the results from Genome-Wide Association
Studies (GWAS) (Mottaz et al., 2008; Ramos et al., 2014) (299 features).
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Fig. 1: Overall schematics of the proposed approach for generating disease-specific drug combinations.
The last 299 features correspond to 299 diseases represented by the
Medical Subject Headings (MeSH) vocabulary (Rogers, 1963).
After removing those genes without KEGG pathway information, the
human interactome used in this study has 13,119 genes and 352,464
physical interactions.
2.2 Disease-disease network
We used a disease-disease network from (Menche et al., 2015) with 299
nodes (diseases), created based on human interactome data (as detailed
earlier), gene expression data (Su et al., 2004), disease-gene associations
(Mottaz et al., 2008; Ramos et al., 2014; Hamosh et al., 2005), Gene
Ontology (Ashburner et al., 2000), symptom similarity (Zhou et al., 2014)
and comorbidity (Hidalgo et al., 2009). The original disease-disease
network is a complete graph with real-valued edges. The edge value
between two diseases shows how much they are topologically separated
from each other. A positive/negative edge weight indicates that that two
disease modules are topologically separated/overlapped. Therefore, we
used zero-weight as the threshold and pruned positive-valued edges, which
results in a disease-disease network of 299 nodes and 5,986 edges (without
weights).
2.3 Disease-gene associations
Weuseddisease-geneassociations from thedatabaseOMIM(Hamosh et al.,
2005). These associations bridge aforementioned gene-gene and disease-
disease networks into a hierarchical graph of genes and diseases, based on
which gene and disease representations will be learned.
2.4 Disease classification
For the purpose of assessment, we used the Comparative Toxicogenomics
Database (CTD) (Davis et al., 2019) to classify diseases into 8 classes
based on their Disease Ontology (DO) terms (Schriml et al., 2012) where
diseases are represented in the MeSH vocabulary (Rogers, 1963). In the
CTD database only 201 of the 299 diseases have a corresponding DO term.
Therefore, for the 98 diseases with missing DO terms we considered the
majority of their parents’ DO terms, if applicable, as their DO terms. With
this approach, we assigned DO terms to 66 such diseases and classified
267 of the 299 diseases. The 32 disease with DO terms still missing are
usually at the top layers of the MeSH tree.
2.5 FDA-approved drugs and drug combinations
To assess our deep generative model for drug combination design (to
be detailed in Sec. 3.2), we consider a comprehensive list of US FDA-
approved combination drugs (1940–2018.9) (Das et al., 2018). Thedataset
contains 419 drug combinations consisting of 328 unique drugs, including
341 (81%), 67 (16%) and 11 (3%) of double, triple and quadruple drug
combinations.
We also utilized the curated drug-disease association from CTD
database (Davis et al., 2019).
3 Methods
We have developed a network-based drug combination generator which
can be utilized in overcoming drug resistance. Representing drugs through
their molecular graphs, we recast the problem of drug combination
generation into network-principled, graph-set generation by incorporating
prior knowledge such as human interactome (gene-gene), disease-
gene, disease-disease, gene pathway, and gene-GO relationships.
Furthermore, we formulate the graph-set generation problem as learning
a Reinforcement Learning (RL) agent that iteratively adds substructures
and edges to each molecular graph in a chemistry- and system-aware
environment. To that end, the RL model is trained to maximize a desired
property Q (for example, therapeutic efficacy for drug combinations)
while following the valency (chemical validity) rules and being similar
in distribution to the prior set of graphs.
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As shown in Fig. 1, the proposed approach consists of: 1) embedding
prior knowledge (different network relationships) through Hierarchical
Variational Graph Auto-Encoders (HVGAE); and 2) generating drug
combinations as graph sets through a reinforcement learning algorithm,
which will be detailed next.
Notations: As both gene-gene and disease-disease networks can be
represented as graphs, notations are differentiated by superscripts ‘g’
and ‘d’ to indicate gene-gene and disease-disease networks, respectively.
Drugs (compounds) are also represented as graphs and notations with ‘k’
in the superscript indicates the k-th drug (graph) in the drug combination
(graph set).
3.1 Hierarchical Variational Graph Auto-Encoders
(HVGAE) for representation learning
Suppose that a gene-gene network is represented as a graph G(g) =
(A(g), {F (g,m)}Mm=1), where A
(g) = [A(g,1), · · · , A(g,ne)] ∈
{0, 1}ng×ng×ne is the adjacency tensor of the gene-gene network with
ng nodes and ne edge types (k-hot encoding of 6 types of aforementioned
physical interactions such as regulatory, binary, metabolic, complex,
kinase and signaling interactions). We also define A˜(g) ∈ {0, 1}ng×ng
to be elemenwise OR of {A(g,1), · · · , A(g,ne)}. Furthermore, F (g,m)
denotes the mth set of node features for gene-gene network where M (5
in the study) represents different types of node features such as pathways,
3 GO terms and gene-disease relationship. We also suppose the disease-
disease network is represented as graph G(d) = (A(d), F (d)), where
A(d) ∈ {0, 1}nd×nd is the adjacency matrix of the disease-disease
network with nd nodes; and F
(d) represents the set of node features
for the disease-disease network.
We have developed a hierarchical embedding with 2 levels. In the first
level, we embed the gene-gene network to get the features related to each
disease and then we incorporate the disease features within the disease-
disease network to embed their relationship. We infer the embedding for
each gene and disease jointly through end-to-end training. The proposed
HVGAE perform probabilistic auto-encoding to capture uncertainty of
representations which is in the same spirit as the variational graph auto-
encoder models introduced in (Kipf and Welling, 2016; Hasanzadeh et al.,
2019; Hajiramezanali et al., 2019) .
3.1.1 First level: Gene-Gene embedding
The inference model for variational embedding of the gene-gene network
is formulated as follows. We first useM graph neural networks (GNNs)
to transform individual nodes’ features inM types and then concatenate
theM sets of results Fˆ (g,m) (m = 1, . . . ,M ) into Fˆ (g):
Fˆ (g,m) = AGG
(
{GNNj(A
(g,j), F (g,m))}, j = 1, · · · , ne
)
Fˆ (g,m) ∈ Rng×Lg , m = 1, · · · ,M
Fˆ (g) = CONCAT({Fˆ (g,m)}Mm=1) ∈ R
ng×MLg , (1)
where AGG is an aggregation function combining output features of
GNNj ’s for each node. We used a two layer fully connected neural
network with ReLU activation functions followed by a single linear layer
in our implementation. We then approximate the posterior distribution
of stochastic latent variables Z(g) (containing z
(g)
i ∈ R
Lg for i =
1, · · · , ng where Lg (32 in this study) is the latent space dimensionality
for the ith gene), with a multivariate Gaussian distribution q(·) given the
gene-gene network’s aggregated node features Fˆ (g) and adjacency tensor
A(g):
q(Z(g)|Fˆ (g), A(g)) =
ng∏
i=1
q(z
(g)
i |Fˆ
(g), A(g)),where
q(z
(g)
i |Fˆ
(g), A(g)) = N (µ
(g)
i , diag(σ
2,(g)
i )),
µ(g) = AGG
(
{GNNµ,g,j(A
(g,j), Fˆ (g))}, j = 1, · · · , ne
)
,
log(σ(g)) = AGG
(
{GNNσ,g,j(A
(g,j), Fˆ (g))}, j = 1, · · · , ne
)
,
µ(g) ∈ Rng×Lg , log(σ(g)) ∈ Rng×Lg . (2)
where Z(g) ∈ Rng×Lg ; µ(g) is the matrix of mean vectors µ
(g)
i ;
and σ(g) the matrix of standard deviation vectors σ
(g)
i (i = 1, . . . , ng).
The generative model for the gene-gene network is formulated as:
p(A˜(g)|Z(g)) =
n∏
i=1
n∏
j=1
p(A˜
(g)
ij
|z
(g)
i
,z
(g)
j
),where
p(A˜
(g)
ij |z
(g)
i ,z
(g)
j ) = σ(z
(g)
i z
(g)T
j ), (3)
andσ(·) is the logistic sigmoid function. The loss for gene-genevariational
embedding is represented as a variational lower bound (ELBO):
L(g) =E
q(Z(g) |Fˆ (g),A(g))[log p(A˜
(g)|Z(g))]
−KL
(
q(Z(g)|Fˆ (g), A(g))||p(Z(g))
)
,
(4)
where KL
(
q(·)||p(·)
)
is the Kullback-Leibler divergence between q(·)
and p(·). We take the Gaussian prior for p(Z(g)) and make use of the
reparameterization trick (Kipf and Welling, 2016) for training.
3.1.2 Second level: disease-disease embedding
The inference model for variational embedding of the disease-disease
network is similar to that of the gene-gene network except that the
disease-disease network’s aggregated node features, Fˆ (d), are derived
through parameterized attentional pooling of Zˆ
(g)
r , latent variables of
genes associated with the rth disease (a subset of Z(g)):
er = v tanh(Zˆ
(g)
r W + b), r = 1, · · · , nd
αr = softmax(er), r = 1, · · · , nd
Fˆ
(d)
r =
∑
i
αr,iZˆ
(g)
r,i , r = 1, · · · , nd
Fˆ (d) = CONCAT({Fˆ
(d)
r }
nd
r=1) ∈ R
nd×Ld , (5)
where αm capture the importance of genes related to the r
th disease
for calculating its latent representations and Ld is the latent space
dimensionality of a disease.
Once Fˆ (d), the disease-disease network’s aggregated node features
for all diseases, are derived; we again define q(Z(d)|Fˆ (d), A(d)) for
the posterior distribution of stochastic latent variables Z(d) similarly
to what we did in Eq. (2) except that AGG functions are removed
since disease-disease network has one binary adjacency matrix; give
the generative decoder p(A(d)|Z(d)) for embedding the disease-disease
network similarly to what we did in Eq. (3); and calculate the variational
lowerbound (ELBO) loss L(d) for the disease-disease network similarly
to what we did in Eq. (4). Details can be found in Supplemental Sec. 1.1.
Both levels of our proposed HVGAE, i.e. gene-gene and disease-
disease variational graph representation learning, are jointly trained in
an end-to-end fashion using the following overall loss:
LHVGAE = L(d) + L(g). (6)
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3.2 Reinforcement learning-based graph-set generator for
drug combinations
In this section, we introduce the reinforcement learning-based drug
combination generator. We will detail 1) the state space of graph sets
(K compounds) and the action space of graph-set growth; 2) multi-
objective rewards including chemical validity and our generalized sliced
Wasserstein reward for individual drugs as well as our newly designed
network principle-based reward for drug combinations; and 3) policy
network that learns to take actions in the rewarding environment.
3.2.1 State and action space
We represent a graph set (drug combination) with K graphs as G =
{G(k)}K
k=1. Each graph G
(k) = (A(k), E(k), F (k)) where A(k) ∈
{0, 1}nk×nk is the adjacency matrix, F (k) ∈ Rnk×φ the node feature
matrix, E(k) ∈ {0, 1}ǫ×nk×nk the edge-conditioned adjacency tensor,
and nk the number of vertices for the k
th graph, respectively; and φ is the
number of features per nodes and ǫ the number of edge types.
The state space G is the set of all K graphs with different numbers
and types of nodes or edges. Specifically, the state of the environment st
at iteration t is defined as the intermediate graph set Gt = {G
(k)
t }
K
k=1
generated so far which is fully observable by the RL agent.
The action space is the set of edges that can be added to the graph set.
An action at at iteration t is analogous to link prediction in each graph
in the set. More specifically, a link can either connect a new subgraph (a
single node/atom or a subgraph/drug-substructure) to a node in G
(k)
t or
connect existing nodes within graph G
(k)
t . The actions can be interpreted
as connecting the current graph with a member of scaffold subgraphs set
C. Mathematically, for G
(k)
t , graph k at step t, the action a
(k)
t is the
quadruple of a
(k)
t = concat(a
(k)
first,t, a
(k)
second,t, a
(k)
edge,t, a
(k)
stop,t).
3.2.2 Multi-objective reward
We have defined a multi-objective reward Rt to satisfy certain
requirements in drug combination therapy. First, a chemical validity
reward maintains that individual compounds are chemically valid. Second,
a novel adversarial reward, generalized sliced Wasserstein GAN (GS-
WGAN), enforces generated compounds are synthesizable and “drug-like"
by following the distribution of synthesizable compounds in the ZINC
database (Irwin and Shoichet, 2005) or FDA-approved drugs. Third, a
network principle-based award would encourage individual drugs to target
the desired disease module but not to overlap in their target sets. Toxicity
due to drug-drug interactions can also be included as a reward. It is
intentionally left out in this study so that toxicity can be evaluated for
drug combinations designed to follow the network principle.
When training the RL agent, we use different reward combinations in
different stages. We first only use the weighted combination of chemical
validity and GS-WGAN awards learning over drug combinations for
all diseases; then we remove the penalized logP (Pen-logP) portion of
chemical validity and add adversarial loss again while learning over drug
combinations for all diseases; and finally use the combination of the three
rewards as in the second stage but focusing on a target disease and possibly
on restricted actions/scaffolds (in a spirit similar to transfer learning). The
three types of rewards are detailed as follows.
Chemical validity reward for individual drugs. A small positive
reward is assigned if the action does not violate valency rules. Otherwise
a small negative reward is assigned. This is an intermediate reward added
at each step. Another reward is on penalized logP (lipophilicity where P is
the octanol-water partition coefficient) or Pen-logP values. The design and
the parameters of this reward is adopted from (You et al., 2018) without
optimization.
Adversarial reward using generalized sliced Wasserstein distance
(GSWD). To ensure that the generated molecules resemble a given set
of molecules (such as those in ZINC or FDA-approved), we deploy
Generative Adversarial Networks (GAN). GANs are very successful at
modeling high-dimensional distributions from given samples. However
they are known to suffer from training unsuitability and cannot generate
diverse samples (a phenomenon known as mode collapse).
Wasserstein GANs (WGAN) have shown to improve stability and
mode collapse by replacing the Jenson-Shannon divergence in original
GAN formulation with the Wasserstein Distance (WD) (Arjovsky et al.,
2017). More specifically, the objective function in WGAN with gradient
penalty (Gulrajani et al., 2017) is defined as follows:
min
θ
max
φ
VW(πθ ,Dφ) + λR(Dφ), (7)
with VW (πθ,Dφ) = Ex∼pr [logDφ(x)]− Ey∼πθ [logDφ(y)],
where pr is the data distribution, λ is a hyper-parameter, R is the Lipschitz
continuity regularization term,Dφ is the critic with parameters φ, and πθ
is the policy (generator) with parameters θ.
Despite theoretical advantages of WGANs, solving equation (7)
is computationally expensive and intractable for high dimensional
data. To overcome this problem, we propose and formulate a novel
Generalized Sliced WGAN (GS-WGAN) which deploys Generalized
Sliced Wasserstein Distance (GSWD) (Kolouri et al., 2019). GSWD,
first, factorizes high-dimensional probabilities into multiple marginal 1D
distributionswith generalizedRadon transform. Then, by taking advantage
of closed form solution ofWasserstein distance in 1D, the distance between
two distributions is approximated by the sum of Wasserstein distances of
marginal 1D distributions. More specifically, let R represent generalized
Radon transform operator. The generalized Radon transform (GRT) of a
probability distribution P(·) which is defined as follows:
RP (t, ψ) =
∫
Rd
P(x) δ(t − f(x, ψ)) dx, (8)
where δ(·) is the one-dimensional Dirac delta function, t ∈ R is a scalar,
ψ is a unit vector in the unit hyper-sphere in ad-dimensional space (Sd−1),
and f is a projection function whose parameters will be learned in training.
Injectivity of the GRT (Beylkin, 1984) is the requirement for the GSWD
to be a valid distance. We use linear project f(x, ψ) here and can easily
extend to two nonlinear cases that maintains the GRT-injectivity (circular
nonlinear projections or homogeneous polynomials with an odd degree).
GSWD between two d-dimensional distributions PX and PY is
therefore defined as:
GSWD(PX , PY ) =
∫
Sd−1
WD(RPX(·, ψ), RPY (·, ψ)) dψ . (9)
The integral in the above equation can be approximated with a Riemann
sum. Knowing the definition of GSWD, we define the objective function
of GS-WGAN as follows:
min
θ
max
φ
VGSW (πθ, Dφ) + λR(Dφ), (10)
s.t. VGSW(πθ,Dφ) =
∫
ψ∈Sd−1
Ex∼pr [logDφ(x)]− (11)
Ey∼πθ [logDφ(y)] dψ ,
where the parameters and notations are the same as defined in Eq. (7).
We note that x and y in Eq. (10) are random variables in Rd,
which is not a reasonable assumption for graphs. To that end, we use an
embedding function g thatmaps each graph to a vector inRd . We use graph
convolutional layers followed by fully connected layers to implement g.
We deploy the same type of neural network architecture for Dφ. We use
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Radvers = −VGSW(πθ,Dφ) as the adversarial reward used together
with other rewards, and optimize the total rewards with a policy gradient
method (Sec. 3.2.3).
Network principle-based reward for drug combinations. Proteins or
genes associated with a disease tend to form a localized neighborhood
disease module rather than scattering randomly in the interactome
(Cheng et al., 2019). A network-based score has been introduced
(Menche et al., 2015), to efficiently capture the network proximity of
a drug (X) and disease (Y ) based on the shortest-path length d(x, y)
between a drug target (x) and a disease protein (y):
Z =
d(X, Y )− d¯
σd
d(X, Y ) =
1
||Y ||
∑
y∈Y
min
x∈X
d(x, y),
(12)
where d(·, ·) is the shortest path distance; d¯ and σd are the mean and
standard deviation of the reference distribution which is corresponding to
the expected network topological distance between two randomly selected
groups of proteins matched to size and degree (connectivity) distribution
as the original disease proteins and drug targets in the human interactome.
Z-score being negative (Z < 0) implies network proximity of disease
module and drug targets which is desirable. From the drug combination
perspective, it has been shown that the complementary exposed drug-
drug relationship has the least side drug side affect and the most drug
combination efficacy (Cheng et al., 2019). Complementary exposed drug-
drug (X1 andX2) relationship means that the drug targets (x1) and drug
targets (x2) are not in the same neighborhood andhas the least overlapping.
Therefore, Cheng et al. have proposed a network-separation score which
is formulated as follow:
sX1,X2 = d(X1, X2)−
d(X1, X1) + d(X2, X2)
2
, (13)
where d(X1,X2) is the mean shortest path distance between drugs X1
and X2; d(X1,X1) and d(X2, X2) are the mean shortest path distance
within drug targets X1 and X2 respectively (Cheng et al., 2019). The
separation score being positive (s > 0) implies to network are separated
from each other which is desirable. We have extended and combined these
scores for general drug combination therapy where we have a set of k
drugs {X1, · · · , Xk} and disease Y :
Rnetwork = λ1
k∑
i=1
∑
j>i
s(Xi, Xj)− λ2
k∑
i=1
Z(Xi, Y ) (14)
However, the exact online calculation of the reward Rnetwork is
infeasible while training across all the diseases and the whole human
interactome with more than 13K nodes and 352K edges. Therefore, we
have developed a relaxed version of the reward which is feasible for online
calculation and correlates with the actual reward. Specifically, we consider
thenormalizedexclusive or (XOR)of intersectionsof diseasemoduleswith
drug targets:
Rˆnetwork =
Y ∩ (X1 ⊕ · · · ⊕Xk)
|Y |
=
(X1 ∩ Y )⊕ · · · ⊕ (Xk ∩ Y )
|Y |
.
(15)
The relaxed network principle-based reward is penalizing a drug
combination if the overlap between drug targets in the disease module
is high, therefore it will prevent the adverse drug-drug interactions. We
scaled the network score by a constant (equals 10) such that the score
would be in the same range as Pen-logP and can use the same weight in
the total reward as Pen-logP did in (You et al., 2018).
For a generated compound, we predict its protein targets by
DeepAffinity (Karimi et al., 2019), judging by whether the predicted IC50
is below 1µM.
3.2.3 Policy Network
Having explained the graph generation environment (various rewards), we
outline the architecture of our proposed policy network. Our method takes
the intermediate graph set Gt and the collection of scaffold subgraphs C
as inputs, and outputs the action at, which predicts a new link for each of
the graphs in Gt (You et al., 2018).
Since the input to our policy network is a set ofK compounds or graphs
{G
(k)
t ∪ C}
K
k=1, we first deploy some layers of graph neural network to
process each of the graphs. More specifically,
X(k) = GNN(k)(G
(k)
t ∪ C), for k = 1, . . . , K, (16)
where GNN(k) is a multilayer graph neural network. The link prediction
based action at iteration t is a concatenation of four components for
each of the K graphs: selection of two nodes, prediction of edge type,
and prediction of termination. Each component is sampled according to
a predicted distribution (You et al., 2018). Details are included in the
Supplemental Sec. 1.2. We note that the first node is always chosen from
Gt while the next node is chosen from {G
(k)
t ∪C}
K
k=1. We also note that
infeasible actions (i.e. actions that do not pass valency check) proposed
by the policy network are rejected and the state remains unchanged. We
adopt Proximal Policy Optimization (PPO) (Schulman et al., 2017), one
of the state-of-the-art policy gradient methods, to train the model.
4 Results
To assess the performance of our proposed model, we have designed a
series of experiments. In section 4.1, we first compare HVGAE to state-
of-art graph embeddingmethods in disease-disease network representation
learning and further include several variants of HVGAE for ablation
studies. We then assess the performance of the proposed reinforcement
learning method in two aspects. In a landscape assessment in Section
4.2, we examine designed pairwise compound-combinations for 299
diseases in quantitative scores of following a network-based principle
(Cheng et al., 2019). InSection4.3, we focuson four case studies involving
multiple diseases of various systems-pharmacology strategies. Ourmethod
is capable of generating higher-order combinations ofK drugs. As FDA-
approved drug combinations are often pairs, here we design compound
pairs from the scaffolds of FDA-approved drug pairs. We further delve into
designed compound pairs to understand the benefit of following network
principles in lowering toxicity from drug-drug interactions. We also do so
to understand their systems pharmacology strategies in comparison to the
FDA-approved drug combinations.
4.1 HVGAE representation compares favorably to
baselines
4.1.1 Experiment setup
To assess the performance of our proposed embedding method HVGAE,
we compare its performance in (disease-disease) network reconstruction
with Node2Vec (Grover and Leskovec, 2016), DeepWalk (Perozzi et al.,
2014), and VGAE (Kipf and Welling, 2016), as well as some variants of
our own model for ablation study. Node2Vec and DeepWalk are random
walk based models that do not capture node attributes, hence we only used
the disease-disease graph structure. For VGAE, we used identity matrix
as node attributes as suggested by the authors.
For our HVGAEdescribed in Sec. 3.1, we also considered two variants
for ablation study: HVGAE-disjoint does not jointly embed gene-gene and
disease-disease networks and does not use attentional pooling for disease
embedding; whereas HVGAE-noAtt just does not use attentional pooling.
Specifically, inHVGAE-disjoint, we, first, learned an embedding for gene-
gene network, then used the sum of mean of the node representations of
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genes affected by a disease as its node attributes. In HVGAE-noAtt, we
jointly learned the representations while using sum of mean of the node
representations of genes as node attributes for disease-disease network.
In node2vec and DeepWalk, the walk length was set to 80, the number
of walks starting at each node was set to 10, and the nodes were embedded
to a 16-dimensional space. The window size was 10 for node2vec while it
is set to 10 in DeepWalk. All models were trained using Adam optimizer.
In VGAE, a 32-dimensional graph convolutional (GC) layer followed by
two 16-dimensional layers was used for mean and variance inference. The
learning rate was set to 0.01.
For HVGAE and its variants (for ablation study), we embed gene
networks in 32 dimensional space using a single GC layer with 32 filters
for each of the 5 types of input followed by a 64-dimensional GC layer
and two 32-dimensional GC layer to infer mean and variance of the
representation. We used a single 32-diensional fully connected (FC) layer
for attention layer. For disease-disease network embedding, we deployed
a single 32-dimensional GC layer followed by two 16-dimensional layer
for mean and variance inference resulting in 16-dimensional embedding
for disease-disease network. Learning rates were set to 0.001. The models
were trained for 1,000 epochs choosing the best representation based on
their the reconstruction performance at each epoch.
4.1.2 Numerical analysis and ablation study for network embedding
Table 1 summarizes the reconstruction performance of the aforementioned
methods. Compared to all baselines, our HVGAE showed the best
performance in all metrics considered. Node2Vec and DeepWalk showed
the worst performance as they only use the graph structure. The
performance of VGAE was very close to DeepWalk. This is due to the
fact that no attributes have been provided to VGAE despite having the
capability of capturing attributes.
Table 1. Graph reconstruction performances (unit: %) in the disease-disease
network using our proposed HVGAE and baselines. F-1 scores are based on
50% threshold.
Method AUC-ROC AP F1-Macro F1-Micro
Node2Vec 79.01 72.82 35.73 51.10
DeepWalk 79.32 73.77 40.28 53.30
VGAE 88.12 85.71 60.19 64.98
HVGAE-disjoint 91.45 90.72 73.45 74.77
HVGAE-noAtt 92.83 92.34 73.81 75.14
HVGAE 96.11 95.89 79.77 80.45
Compared to VGAE, HVGAE-disjoint without joint embedding or
attentional pooling still saw better performance, which suggests that
the attributes generated by the gene-gene network contains meaningful
features about the disease-disease network. The slight performance gain
from HVGAE-disjoint to HVGAE-noAtt shows that joint learning of both
networks hierarchically helps to render more informative features for the
disease-disease network. Finally, HVGAE had another performance boost
compared to HVGAE-noAtt and outperformed all competing methods,
which shows the benefit of attentional pooling. Specifically, the attention
layer of HVGAE allows the model to produce features that are specifically
informative for the disease-disease network representation learning.
4.2 Our model generates drug combinations following
network principles across diseases
4.2.1 Experiment setup
We have trained the proposed reinforcement model in 3 stages using
different rewards, disease sets, and action spaces to increasingly focus on a
target disease while exploiting all diseases whose representations already
jointly embed gene-gene, disease-disease, and gene-disease networks.
In the first stage, we train the model to only generate drug-like small-
molecules which follow the chemistry valency reward, lipophilicity reward
(logP where P is the octanol-water partition coefficient) (You et al., 2018),
and our novel adversarial reward for individual compounds. In this study,
we trained the model for 3 days (4,800 iterations) to learn to follow the
valency conditions and promote high logP for generated compounds.
In the second stage, we start from the trained model at the end of the
first stage (“warm-start” or “pre-training”). And we continue to train the
model to generate good drug combinations across all diseases. We do so by
adding the network principle-based reward for compound combinations
and sequentially generating drug combinations for each disease one by
one. Then, we calculate the network-based score for the generated drug
combinations at the last epoch across disease ontologies and compare them
with the FDA-approved melanoma drug combinations’ network-based
score. In this study, we trained the model for 1,500 iterations to generate
drug combinations across all 299 diseases. In each iteration, wegenerated 8
drug combinations for a given disease. We adopted PPO (Schulman et al.,
2017) with a learning rate of 0.001 to train the proposed RL for both stages.
The last stage is disease-specific and will be detailed in Sec. 4.3.
4.2.2 Numerical analysis
Across disease ontologies we quantify the performance of the proposedRL
(stage 2 model first) using quantitative scores of compound-combinations
following a network-based principle (Cheng et al., 2019). We consider
the generated combinations in the last epoch (the last 299 iterations)
and calculate the network score Rˆnetwork based on disease ontologies.
We asses our model based on two versions of disease classification,
original disease ontology and its extension, explained in Sec. 2.4. Table 2
summarizes the network-based scores for our model. Specifically, suppose
that the set of targets for drug 1 and 2 are represented by A and B
whereas the disease module is the universal set Ω, we report the portion
exclusively covered by drug 1 (ηA−B ), exclusively covered by drug 2
(ηB−A), overlapped by both (ηA∩B), and collectively by both (ηA∪B ).
As a reference, we calculated the corresponding network scores for 3
FDA-approved drug combinations for melanoma.
Based on the results shown in Table 2, we note that across all disease
classes, the designed compound combinations learned in an environment,
where the network principle(Cheng et al., 2019)was rewarded, did achieve
the desired performances. Specifically, their overlaps in disease modules
were low as ηA∩B fractions are around 0.1; whereas their joint coverage in
disease modules was high as ηA∪B fractions were in the range of 0.4–0.5
for all diseases.
Table 2. Network-based score for the generated drug combinations based on
disease ontology classifications.
Disease Ontology Disease Ontology extended
ηA−B ηB−A ηA∩B ηA∪B ηA−B ηB−A ηA∩B ηA∪B
infectious disease 0.25 0.10 0.06 0.41 0.20 0.07 0.05 0.33
disease of anatomical entity 0.27 0.12 0.10 0.49 0.26 0.11 0.09 0.48
disease of cellular proliferation 0.25 0.09 0.07 0.42 0.25 0.10 0.08 0.44
disease of mental health 0.22 0.11 0.10 0.43 0.22 0.11 0.10 0.43
disease of metabolism 0.22 0.13 0.10 0.46 0.23 0.14 0.11 0.48
genetic disease 0.23 0.15 0.11 0.4 0.23 0.15 0.11 0.49
syndrome 0.22 0.11 0.11 0.44 0.22 0.11 0.11 0.44
Compared to a few FDA-approved drugs for melanoma in Table 3, we
notice that the designed compound combinations had similar exclusive
coverage (ηA−B and ηB−A) as the drug combinations. However,
the overlapping and overall coverage (ηA∩B and ηA∪B ) were both
much higher in FDA-approved drug combinations than the designed.
Improvements could be made by training the RL agent longer, as these
scores had already been improving during the limited training process
8 Karimi, Hasanzadeh and Shen
under computational restrictions. More improvement can be made by
adjusting the network-based reward as well.
Table 3. Network-based scores for FDA-approved melanoma drug-
combinations.
ηA−B ηB−A ηA∩B ηA∪B
Dabrafenib + Trametinib 0.05 0.21 0.55 0.81
Encorafenib + Binimetinib 0.21 0.05 0.53 0.86
Vemurafenib + Cobimetinib 0.05 0.27 0.36 0.68
4.3 Case studies for specific diseases
4.3.1 Experiment Setup
In the third and last stage of RL model training, we start from the stage 2
model and generate drug combinations for a fixed target disease and can
choose scaffold libraries specific to the disease. In parallel, we trained
the model for 500 iterations (roughly 1 day) to generate 4,000 drug
combinations specifically for each of 4 diseases featuring various drug-
combination strategies: melanoma, lung cancer, ovarian cancer, and breast
cancer. In all cases, we started with the Murcko scaffolds of specific
FDA-approved drug combinations to be detailed next.
Melanoma: Different targets in the same pathway. Resistance to BRAF
kinase inhibitors is associated with reactivation of the mitogen-activated
protein kinase (MAPK) pathway. There is, thus, a phase 1 and 2 trial
of combined treatment with Dabrafenib, a selective BRAF inhibitor, and
Trametinib, a selective MAPK kinase (MEK) inhibitor. As melanoma is
not one of the 299 diseases, we chose broader neoplasm as an alternative.
To compensate the loss of focus on target disease, we design compound
pairs from Murcko scaffolds of Dabrafenib + Trametinib.
Lung and ovarian cancers: Targeting parallel pathways. MAPKand PI3K
signaling pathways are parallels important for treating many cancers
including lung and ovarian cancers (Day and Siu, 2016; Bedard et al.,
2015). Clinical data suggest that dual blockade of these parallel
pathways has synergistic effects. Buparlisib (BKM120) and Trametinib
(GSK1120212; Mekinist) are as a drug combination therapy are used for
the purpose. Specifically, Buparlisib is a potent and highly specific PI3K
inhibitor, whereas Trametinib is a highly selective, allosteric inhibitor of
MEK1/MEK2 activation and kinase activity (Bedard et al., 2015).
Breast cancer: Reverse resistance. Endocrine therapies, including
Fulvestrant, are the main treatment for hormone receptor–positive breast
cancers (80% of breast cancers) (Turner et al., 2015). However, they could
confer resistance to patients during or after the treatment. A phase 3 study
is using Fulvestrant and Palbociclib as a combination therapy to reverse
the resistance. Fulvestrant and Palbociclib are targeting different genes in
different pathways. Specifically, Fulvestrant targets estrogen receptor (ER)
α in estrogen signaling pathway and Palbociclib targets cyclin-dependent
kinases 4 and 6 (CDK4 and CDK6) in cell cycle pathway (Turner et al.,
2015).
4.3.2 Baseline methods for drug pair combination
Since our proposed method is the first to generate drug combinations for
specific diseases, we consider the following baseline methods to compare
with: 1) random selection of 1,000 pairs from 8,724 small-molecule
drugs in Drugbank (Wishart et al., 2018); 2) 628 FDA-approved drug
combinations curated by (Cheng et al., 2019) for hypertension and cancers
(our case studies are on 4 types of cancers); 3) random selection of 1,000
pairs of FDA-approved drugs for the given disease, based on drug-disease
dataset "SCMFDD-L" (Zhang et al., 2018).
4.3.3 Designed pairs follow network principles and improve toxicity
We first compare the compound combinations designed by our model and
those from the baselines using the network score that reflects the network-
based principle. Fig. 2(a)–(d) shows that our designed combinations
in all 4 cases, with higher network scores in distribution, respected
the network principle more than the baselines (including the FDA-
approved pairs not necessarily specific for the target disease). The
observation is statistically significant with P-values ranging from 6E-
74 to 7E-7 (one-sided Kolmogorov-Smirnov [KS] test; see more details
in the Supplemental Tables S2 and S3). Such a result is thanks to the
network-principled reward we introduced.
We also examine whether drug combinations designed to follow
the network principle could reduce toxicity from drug-drug interactions
(DDIs). DDIs are crucial when using drug combinations since they may
trigger unexpected pharmacological effects, including adverse drug events
(ADEs). We used a deep-learning model DeepDDI (Ryu et al., 2018) with
amean accuracy of 92.4% to predict for each combination the probabilities
of 86 types of DDIs (we manually split them into 16 positive and 70
negatives; see details in the Supplemental Sec. 1.3). To summarize over the
DDIs, we considered both maximum and mean probabilities of positive or
negative ones. Andwe compared those distributions between our designed
pairs and baselines in each disease.
Fig. 2(e)–(h), using the mean probability among negative DDIs, shows
that our compound pairs designed for all 4 diseases were predicted to
have less chances of toxicity compared to the baselines. One-sided KS
tests attested to the statistical significance of the observation as P-values
ranged between 2E-166 and 2E-53. More analyses can be found in the
Supplemental Sec. 3.
Taken together, Fig. 2 suggested that following the network principle
in designing drug combinations would help reduce toxicity due to DDIs.
4.3.4 Designed pairs reproduce approved polyphamacology strategies
We next examine the DeepAffinity-predicted target genes of our designed
pairs and compare them to the polyphamacology strategies outlined in
Sec. 4.3.1 for each disease. Since improved network scores have been
shown to correlate with lower toxicity, we used the scores to filter the
4,000 combinations designed for each disease. specifically, we retained
combinations with network scores above 0.5 and ηA∩B below 0.1. These
designs are shared along with the codes.
For melanoma, out of 69 combination designs retained, 26% were
predicted to jointly cover BRAF andMEK genes in a complementary way.
In other words, one molecule only targets BRAF and the other only targets
MEK, according to our DeepAffinity(Karimi et al., 2019)-predicted IC50,
echoing the systems pharmacology strategy of the drug combination of
Dabrafenib and Trametinib. There were also other designs which demand
further examination and potentially contain novel strategies. All retained
designs were predicted to target the MAPK pathway to which BRAF and
MEK belong.
For lung and ovarian cancers, the same filtering criteria retained 204
(896) compound combinations designed for lung (ovarian) cancer. As
diseasemodules can be limited, MEK1/2 does not exist in the usedmodules
for lung (ovarian cancer) and a gene-level analysis cannot be performed
as the melanoma case. Instead, we performed the pathway-level analysis
and found that 50.9% (45.2%) of combination designs for ovarian (lung)
cancer were predicted to jointly and complementarily cover the MAPK
and PI3K signaling pathways, which echoes the combination of Buparlisib
and Trametinib. Moreover, 99.5% (100%) of these retained designs were
predicted to jointly target both pathways for ovarian (lung) cancer.
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Fig. 2: Comparison of network score and toxicity of RL-generated pairs of compounds (our proposed method) with three baselines, i.e. random pairs of
DrugBank compounds, FDA-approved drug pairs, and random pairs of FDA-approved drugs for four case-study diseases.
For breast cancer, 77 designed compound-combinations passed the
filters. As CDK4/6 does not belong to the breast-cancer module due
to the limitation of disease modules used, we again only performed
a pathway-level analysis. 9% of the combinations were predicted to
jointly and complementarily cover ER-signaling and cell-cycle pathways
as Fulvestrant and Palbociclib do. Also, 74% of the retained combinations
jointly cover these pathways. These two portions suggest that many
designed combinations were predicted to simultaneously target both
pathways (with possible overlapping genes). If we consider PI3K
signaling rather than cell cycle pathway for CDK4/6, 15.5% of retained
drug combinations were predicted to jointly and complementarily cover
estrogen and PI3K signaling pathways and all of them did jointly.
4.3.5 Ablation study for RL-based drug-combination generation
Besides HVGAE for network and disease embedding, two of our novel
contributions in RL-based drug set generations were network-principled
reward and adversarial reward through GS-WGAN. To assess the effects
of these contributions to our model, we performed ablation study for stage
3 using the case of melanoma. We ablated the originally proposed model
in two ways: removing the network-principled reward or replacing the GS-
WGAN adversarial reward with the previously-used GAN reward based
on Jenson-Shannon (JS) divergence. Results in Fig. 3 suggested that both
rewards led to faster initial growth and higher saturation values in network-
based scores.
5 Conclusion
In response to the need of accelerated and principled drug-combination
design, we have recast the problem as graph set generation in a chemically
and net-biologically valid environment and developed the first deep
generative model with novel adversarial award and drug-combination
award in reinforcement learning for the purpose. We have also designed
hierarchical variation graph auto-encoders (HGVAE) to jointly embed
domain knowledge such as gene-gene, disease-disease, gene-disease
networks and learn disease representations to be conditioned on in the
generative model for disease-specific drug combination. Our results
indicate that HGVAE learns integrative gene and disease representations
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Fig. 3: Ablation study for RL: Best network scores achieved by three
variants of the proposed method over training iterations.
that are much more generalizable and informative than state-of-the-
art graph unsupervised-learning methods. The results also indicate that
the reinforcement learning model learns to generate drug combinations
following a network-based principle thanks to our adversarial and drug-
combination rewards. Case studies involving four diseases indicate that
drug combinations designed to follow network principles tend to have low
toxicity from drug-drug interactions. These designs also encode systems
pharmacology strategies echoing FDA-approved drug combinations as
well as other potentially promising strategies. As the first generative
model for disease-specific drug combination design, our study allows
for assessing and following network-based mechanistic hypotheses in
efficiently searching the chemical combinatorial space and effectively
designing drug combinations.
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